STAT1 and graft versus host disease: The 129.Stat1–/– recipients experienced significantly accelerated mortality (Figure 1A, median survival time [MST] of 5 days vs. 7.5 days, log-rank test P < 0.0001) and exacerbated morbidity, as measured by GVHD clinical scores (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI125986DS1).